Management of low (favourable)-risk prostate cancer

BJU International

Volumn 108, Issue 11, 2011, Pages 1684-1695

  Carter, H Ballentine ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

favourable risk; low risk; prostate cancer

Indexed keywords

ANTIANDROGEN; PROSTATE SPECIFIC ANTIGEN;

AGE; ANTIGEN DETECTION; BRACHYTHERAPY; CANCER GRADING; CANCER MORTALITY; CANCER RISK; CANCER SCREENING; CANCER SIZE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL (TOPIC); COMPUTER SIMULATION; EVIDENCE BASED MEDICINE; EXTERNAL BEAM RADIOTHERAPY; GLEASON SCORE; GOOD CLINICAL PRACTICE; HEALTH STATUS; HIGH INTENSITY FOCUSED ULTRASOUND; HUMAN; LAPAROSCOPIC SURGERY; LIFE EXPECTANCY; MEDICAL DECISION MAKING; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PATIENT ATTITUDE; PHYSICIAN ATTITUDE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; QUALITY OF LIFE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; TREATMENT INDICATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WATCHFUL WAITING; ADVERSE EVENT; CANCER EPIDEMIOLOGY; CANCER GROWTH; CANCER LOCALIZATION; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SPECIFIC SURVIVAL; HEALTH CARE COST; METASTASIS FREE SURVIVAL; PATIENT DECISION MAKING; PATIENT PREFERENCE; PREVALENCE;

AGED; EVIDENCE-BASED MEDICINE; FORECASTING; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; RISK ASSESSMENT; RISK FACTORS; UNNECESSARY PROCEDURES; WATCHFUL WAITING;

EID: 81255184643     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2010.10489.x     Document Type: Review

References (67)

1. Welch HG, Black WC,. Overdiagnosis in cancer. J Natl Cancer Inst 2010; 102: 605-13
2. Lu-Yao GL, Albertsen PC, Moore DF, et al,. Outcomes of localized prostate cancer following conservative management. JAMA 2009; 302: 1202-9
3. Cooperberg MR, Broering JM, Carroll PR,. Time trends and local variation in primary treatment of localized prostate cancer. J Clin Oncol 2010; 28: 1117-23
4. Walsh PC,. 2008 Whitmore Lecture: radical prostatectomy-where we were and where we are going. Urol Oncol 2009; 27: 246-50
5. Severson RK, Montie JE, Porter AT, Demers RY,. Recent trends in incidence and treatment of prostate cancer among elderly men. J Natl Cancer Inst 1995; 87: 532-4
6. Etzioni R, Tsodikov A, Mariotto A, et al,. Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control 2008; 19: 175-81
7. Hugosson J, Carlsson S, Aus G, et al,. Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 2010; 11: 725-32
8. Schroder FH, Hugosson J, Roobol MJ, et al,. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360: 1320-8
9. Miller DC, Gruber SB, Hollenbeck BK, Montie JE, Wei JT,. Incidence of initial local therapy among men with lower-risk prostate cancer in the United States. J Natl Cancer Inst 2006; 98: 1134-41 (Pubitemid 44288788)
10. Shao YH, Albertsen PC, Roberts CB, et al,. Risk profiles and treatment patterns among men diagnosed as having prostate cancer and a prostate-specific antigen level below 4.0 ng/ml. Arch Intern Med 2010; 170: 1256-61
11. Welch HG, Albertsen PC,. Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 2009; 101: 1325-9
12. Lughezzani G, Briganti A, Karakiewicz PI, et al,. Predictive and prognostic models in radical prostatectomy candidates: a critical analysis of the literature. Eur Urol 2010; 58: 687-700
13. D'Amico AV, Whittington R, Malkowicz SB, et al,. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969-74 (Pubitemid 28445094)
14. Epstein JI, Walsh PC, Carmichael M, Brendler CB,. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 1994; 271: 368-74 (Pubitemid 24037911)
15. Mohler J, Bahnson RR, Boston B, et al,. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010; 8: 162-200
16. Heidenreich A, Bellmunt J, Bolla M, et al,. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71
17. Wilt TJ, MacDonald R, Rutks I, Shamliyan TA, Taylor BC, Kane RL,. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. Ann Intern Med 2008; 148: 435-48 (Pubitemid 351665443)
18. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL,. Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 2011; 29: 1335-41
19. Bill-Axelson A, Holmberg L, Filen F, et al,. Radical prostatectomy versus watchful waiting in localized prostate cancer: the Scandinavian prostate cancer group-4 randomized trial. J Natl Cancer Inst 2008; 100: 1144-54
20. Eggener SE, Scardino PT, Walsh PC, et al,. Predicting 15-year prostate cancer specific mortality after radical prostatectomy. J Urol 2011; 185: 869-75
21. Albertsen PC, Hanley JA, Fine J,. 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 2005; 293: 2095-101 (Pubitemid 40617061)
22. van den Bergh RC, Steyerberg EW, Khatami A, et al,. Is delayed radical prostatectomy in men with low-risk screen-detected prostate cancer associated with a higher risk of unfavorable outcomes? Cancer 2010; 116: 1281-90
23. Albertsen PC, Hanley JA, Barrows GH, et al,. Prostate cancer and the Will Rogers phenomenon. J Natl Cancer Inst 2005; 97: 1248-53 (Pubitemid 41535365)
24. Hamilton AS, Albertsen PC, Johnson TK, et al,. Trends in the treatment of localized prostate cancer using supplemented cancer registry data. BJU Int 2011; 107: 576-84
25. Shahinian VB, Kuo YF, Freeman JL, Goodwin JS,. Determinants of androgen deprivation therapy use for prostate cancer: role of the urologist. J Natl Cancer Inst 2006; 98: 839-45 (Pubitemid 43932049)
26. Shahinian VB, Kuo YF, Gilbert SM,. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med 2010; 363: 1822-32
27. Wolf JS Jr, Hubbard H, Faraday MM, Forrest JB,. Clinical practice guidelines to inform evidence-based clinical practice. World J Urol 2011; 29: 303-9
28. Furlow B,. US urology clinics overprescribe prostate radiotherapy. Lancet Oncol 2011; 12: 122
29. Draisma G, Boer R, Otto SJ, et al,. Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-78 (Pubitemid 36833878)
30. Parker C, Muston D, Melia J, Moss S, Dearnaley D,. A model of the natural history of screen-detected prostate cancer, and the effect of radical treatment on overall survival. Br J Cancer 2006; 94: 1361-8 (Pubitemid 43772267)
31. Thompson IM, Pauler DK, Goodman PJ, et al,. Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-46
32. Haas GP, Delongchamps NB, Jones RF, et al,. Needle biopsies on autopsy prostates: sensitivity of cancer detection based on true prevalence. J Natl Cancer Inst 2007; 99: 1484-9
33. Howard DH,. Life expectancy and the value of early detection. J Health Econ 2005; 24: 891-906 (Pubitemid 41207901)
34. Cooperberg MR, Broering JM, Kantoff PW, Carroll PR,. Contemporary trends in low risk prostate cancer: risk assessment and treatment. J Urol 2007; 178: S14-9 (Pubitemid 47224952)
35. Barbash GI, Glied SA,. New technology and health care costs-the case of robot-assisted surgery. N Engl J Med 2010; 363: 701-4
36. Makarov DV, Yu JB, Desai RA, Penson DF, Gross CP,. The association between diffusion of the surgical robot and radical prostatectomy rates. Med Care 2011; 49: 333-9
37. Andriole GL, Crawford ED, Grubb RL III, et al,. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360: 1310-9
38. McVey GP, McPhail S, Fowler S, McIntosh G, Gillatt D, Parker CC,. Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int 2010; 106: 1161-4
39. Barry MJ,. The prostate cancer treatment bazaar: comment on Physician visits prior to treatment for clinically localized prostate cancer. Arch Intern Med 2010; 170: 450-2
40. Sanda MG, Dunn RL, Michalski J, et al,. Quality of life and satisfaction with outcome among prostate-cancer survivors. N Engl J Med 2008; 358: 1250-61 (Pubitemid 351439226)
41. Dong F, Kattan MW, Steyerberg EW, et al,. Validation of pretreatment nomograms for predicting indolent prostate cancer: efficacy in contemporary urological practice. J Urol 2008; 180: 150-4
42. Nguyen CT, Kattan MW,. Development of a prostate cancer metagram: a solution to the dilemma of which prediction tool to use in patient counseling. Cancer 2009; 115 (Suppl.): 3039-45
43. Jeldres C, Latouff JB, Saad F,. Predicting life expectancy in prostate cancer patients. Curr Opin Support Palliat Care 2009; 3: 166-9
44. Widmark A, Klepp O, Solberg A, et al,. Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet 2009; 373: 301-8
45. Sheridan TB, Carter HB, Wang W, Landis PB, Epstein JI,. Change in prostate cancer grade over time in men followed expectantly for stage T1c disease. J Urol 2008; 179: 901-5
46. Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J,. Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study. J Natl Cancer Inst 2010; 102: 950-8
47. Shappley WV III, Kenfield SA, Kasperzyk JL, et al,. Prospective study of determinants and outcomes of deferred treatment or watchful waiting among men with prostate cancer in a nationwide cohort. J Clin Oncol 2009; 27: 4980-5
48. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A,. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J Clin Oncol 2010; 28: 126-31
49. Krakowsky Y, Loblaw A, Klotz L,. Prostate cancer death of men treated with initial active surveillance: clinical and biochemical characteristics. J Urol 2010; 184: 131-5
50. Eggener SE, Mueller A, Berglund RK, et al,. A multi-institutional evaluation of active surveillance for low risk prostate cancer. J Urol 2009; 181: 1635-41
51. Dall'Era MA, Cooperberg MR, Chan JM, et al,. Active surveillance for early-stage prostate cancer: review of the current literature. Cancer 2008; 112: 1650-9 (Pubitemid 351536825)
52. Dall'Era MA, Carroll PR,. Outcomes and follow-up strategies for patients on active surveillance. Curr Opin Urol 2009; 19: 258-62
53. Holmstrom B, Holmberg E, Egevad L, et al,. Outcome of primary versus deferred radical prostatectomy in the National Prostate Cancer Register of Sweden Follow-Up Study. J Urol 2010; 184: 1322-7
54. Hayes JH, Ollendorf DA, Pearson SD, et al,. Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis. JAMA 2010; 304: 2373-80
55. Liu DLH, Frick KD, Carter HB,. Which men with low-risk prostate cancer should be treated? Med Decis Making 2011; 31: E95-118
56. Tosoian JJ, Trock BJ, Landis P, et al,. Active surveillance program for prostate cancer: an update of the Johns Hopkins experience. J Clin Oncol 2011; 29: 2185-90
57. Tseng KS, Landis P, Epstein JI, Trock BJ, Carter HB,. Risk stratification of men choosing surveillance for low risk prostate cancer. J Urol 2010; 183: 1779-85
58. San Francisco IF, Werner L, Regan MM, Garnick MB, Bubley G, DeWolf WC,. Risk stratification and validation of prostate specific antigen density as independent predictor of progression in men with low risk prostate cancer during active surveillance. J Urol 2011; 185: 471-6
59. Conti SL, Dall'era M, Fradet V, Cowan JE, Simko J, Carroll PR,. Pathological outcomes of candidates for active surveillance of prostate cancer. J Urol 2009; 181: 1628-34
60. Kane CJ, Im R, Amling CL, et al,. Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology 2010; 76: 695-700
61. Administration SS,. Period Life Table, 2006. Social Security Administration; 2010. Available at:. Accessed June 2011
62. Garber K,. Beyond sequencing: new diagnostic tests turn to pathways. J Natl Cancer Inst 2011; 103: 290-2
63. Cuzick J, Swanson GP, Fisher G, et al,. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. Lancet Oncol 2011; 12: 245-55
64. Ding Z, Wu CJ, Chu GC, et al,. SMAD4-dependent barrier constrains prostate cancer growth and metastatic progression. Nature 2011; 470: 269-73
65. Zaheer A, Cho SY, Pomper MG,. New agents and techniques for imaging prostate cancer. J Nucl Med 2009; 50: 1387-90
66. Wilt TJ, Brawer MK, Barry MJ, et al,. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials 2009; 30: 81-7
67. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL,. Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 2010; 46: 3095-101